Non-random Escape Pathways from a Broadly Neutralizing Human Monoclonal Antibody Map to a Highly Conserved Region on the Hepatitis C Virus E2 Glycoprotein Encompassing Amino Acids 412–423

English version České info

An effective hepatitis C virus (HCV) vaccine will require information on epitopes that are responsible for protective antibodies against this highly diverse virus. A region known to be highly conserved and responsible for broadly neutralizing antibodies is located on the E2 glycoprotein at 412–423. To test whether HCV can escape from human antibodies against this region, infectious virus was passaged in culture in increasing concentrations of a human monoclonal antibody to 412–423. Multiple pathways of viral escape were identified at different levels of antibody concentrations. Some of the escape virions were stable and were more robust than wild-type virus. Other escape virions were unstable and had compromised in vitro viral fitness. Collectively, these findings underscore the difficulties in HCV vaccine development and the need to induce high potency antibodies not associated with viral escape.

Vyšlo v časopise: Non-random Escape Pathways from a Broadly Neutralizing Human Monoclonal Antibody Map to a Highly Conserved Region on the Hepatitis C Virus E2 Glycoprotein Encompassing Amino Acids 412–423. PLoS Pathog 10(8): e32767. doi:10.1371/journal.ppat.1004297
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1004297

Souhrn

Zdroje

1. World Health Organization. Hepatitis C. Fact sheet number 164. http://who.int/mediacentre/factsheets/fs164/en/#content (2013). WHO website (online).

2. JacobsonIM, GordonSC, KowdleyKV, YoshidaEM, Rodriguez-TorresM, et al. (2013) Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 368: 1867–1877.

3. GaneEJ, StedmanCA, HylandRH, DingX, SvarovskaiaE, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 368: 34–44.

4. LawitzE, MangiaA, WylesD, Rodriguez-TorresM, HassaneinT, et al. (2013) Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 368: 1878–1887.

5. LiangTJ, GhanyMG (2013) Current and future therapies for hepatitis C virus infection. N Engl J Med 368: 1907–1917.

6. ScheelTK, RiceCM (2013) Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med 19: 837–849.

7. BartoschB, BukhJ, MeunierJC, GranierC, EngleRE, et al. (2003) In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes. Proc Natl Acad Sci U S A 100: 14199–14204.

8. PestkaJM, ZeiselMB, BlaserE, SchurmannP, BartoschB, et al. (2007) Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci U S A 104: 6025–6030.

9. LavilletteD, MoriceY, GermanidisG, DonotP, SoulierA, et al. (2005) Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection. J Virol 79: 6023–6034.

10. OsburnWO, FisherBE, DowdKA, UrbanG, LiuL, et al. (2010) Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology 138: 315–324.

11. LawM, MaruyamaT, LewisJ, GiangE, TarrAW, et al. (2008) Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med 14: 25–27.

12. MeulemanP, BukhJ, VerhoyeL, FarhoudiA, VanwolleghemT, et al. (2011) In vivo evaluation of the cross-genotype neutralizing activity of polyclonal antibodies against hepatitis C virus. Hepatology 53: 755–762.

13. DornerM, HorwitzJA, RobbinsJB, BarryWT, FengQ, et al. (2011) A genetically humanized mouse model for hepatitis C virus infection. Nature 474: 208–211.

14. BartoschB, DubuissonJ, CossetFL (2003) Infectious hepatitis C virus pseudo-particles containing functional E1–E2 envelope protein complexes. J Exp Med 197: 633–642.

15. DrummerHE, MaerzA, PoumbouriosP (2003) Cell surface expression of functional hepatitis C virus E1 and E2 glycoproteins. FEBS Lett 546: 385–390.

16. HsuM, ZhangJ, FlintM, LogvinoffC, Cheng-MayerC, et al. (2003) Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci U S A 100: 7271–7276.

17. ZeiselMB, FelmleeDJ, BaumertTF (2013) Hepatitis C virus entry. Curr Top Microbiol Immunol 369: 87–112.

18. HelleF, GoffardA, MorelV, DuverlieG, McKeatingJ, et al. (2007) The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein. J Virol 81: 8101–8111.

19. FalkowskaE, KajumoF, GarciaE, ReinusJ, DragicT (2007) Hepatitis C virus envelope glycoprotein E2 glycans modulate entry, CD81 binding, and neutralization. J Virol 81: 8072–8079.

20. GoffardA, CallensN, BartoschB, WychowskiC, CossetF-L, et al. (2005) Role of N-Linked Glycans in the Functions of Hepatitis C Virus Envelope Glycoproteins. J Virol 79: 8400–8409.

21. HelleF, VieyresG, ElkriefL, PopescuCI, WychowskiC, et al. (2010) Role of N-linked glycans in the functions of hepatitis C virus envelope proteins incorporated into infectious virions. J Virol 84: 11905–11915.

22. FarciP, ShimodaA, WongD, CabezonT, De GioannisD, et al. (1996) Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci U S A 93: 15394–15399.

23. ShimizuYK, HijikataM, IwamotoA, AlterHJ, PurcellRH, et al. (1994) Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses. J Virol 68: 1494–1500.

24. von HahnT, YoonJC, AlterH, RiceCM, RehermannB, et al. (2007) Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology 132: 667–678.

25. KeckZ, WangW, WangY, LauP, CarlsenTH, et al. (2013) Cooperativity in virus neutralization by human monoclonal antibodies to two adjacent regions located at the amino terminus of hepatitis C virus e2 glycoprotein. J Virol 87: 37–51.

26. KeckZY, LiTK, XiaJ, BartoschB, CossetFL, et al. (2005) Analysis of a highly flexible conformational immunogenic domain a in hepatitis C virus E2. J Virol 79: 13199–13208.

27. KeckZY, Op De BeeckA, HadlockKG, XiaJ, LiTK, et al. (2004) Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct properties and biological functions. J Virol 78: 9224–9232.

28. KeckZY, XiaJ, WangY, WangW, KreyT, et al. (2012) Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate. PLoS Pathog 8: e1002653.

29. OwsiankaAM, TarrAW, KeckZ, LiT, WitteveldtJ, et al. (2008) Broadly neutralizing human monoclonal antibodies to Hepatitis C Virus E2 glycoprotein. J Gen Virol 89: 653–659.

30. KeckZY, LiSH, XiaJ, von HahnT, BalfeP, et al. (2009) Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity. J Virol 83: 6149–6160.

31. KeckZY, OlsonO, Gal-TanamyM, XiaJ, PatelAH, et al. (2008) A point mutation leading to hepatitis C virus escape from neutralization by a monoclonal antibody to a conserved conformational epitope. J Virol 82: 6067–6072.

32. KeckZY, SahaA, XiaJ, WangY, LauP, et al. (2011) Mapping a region of hepatitis C virus E2 that is responsible for escape from neutralizing antibodies and a core CD81-binding region that does not tolerate neutralization escape mutations. J Virol 85: 10451–10463.

33. TarrAW, UrbanowiczRA, JayarajD, BrownRJ, McKeatingJA, et al. (2012) Naturally occurring antibodies that recognize linear epitopes in the amino terminus of the hepatitis C virus e2 protein confer noninterfering, additive neutralization. J Virol 86: 2739–2749.

34. TarrAW, OwsiankaAM, JayarajD, BrownRJ, HicklingTP, et al. (2007) Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33. J Gen Virol 88: 2991–3001.

35. SaboMC, LucaVC, PrentoeJ, HopcraftSE, BlightKJ, et al. (2011) Neutralizing monoclonal antibodies against hepatitis C virus E2 protein bind discontinuous epitopes and inhibit infection at a postattachment step. J Virol 85: 7005–7019.

36. FlintM, MaidensC, Loomis-PriceLD, ShottonC, DubuissonJ, et al. (1999) Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. J Virol 73: 6235–6244.

37. OwsiankaA, TarrAW, JuttlaVS, LavilletteD, BartoschB, et al. (2005) Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. J Virol 79: 11095–11104.

38. BroeringTJ, GarrityKA, BoatrightNK, SloanSE, SandorF, et al. (2009) Identification and characterization of broadly neutralizing human monoclonal antibodies directed against the E2 envelope glycoprotein of hepatitis C virus. J Virol 83: 12473–12482.

39. KongL, GiangE, NieusmaT, RobbinsJB, DellerMC, et al. (2012) Structure of hepatitis C virus envelope glycoprotein E2 antigenic site 412 to 423 in complex with antibody AP33. J Virol 86: 13085–13088.

40. PotterJA, OwsiankaAM, JefferyN, MatthewsDJ, KeckZY, et al. (2012) Toward a hepatitis C virus vaccine: the structural basis of hepatitis C virus neutralization by AP33, a broadly neutralizing antibody. J Virol 86: 12923–12932.

41. KongL, GiangE, RobbinsJB, StanfieldRL, BurtonDR, et al. (2012) Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1. Proc Natl Acad Sci U S A 109: 9499–9504.

42. OwsiankaAM, TimmsJM, TarrAW, BrownRJ, HicklingTP, et al. (2006) Identification of conserved residues in the E2 envelope glycoprotein of the hepatitis C virus that are critical for CD81 binding. J Virol 80: 8695–8704.

43. PantuaH, DiaoJ, UltschM, HazenM, MathieuM, et al. (2013) Glycan shifting on hepatitis C virus (HCV) E2 glycoprotein is a mechanism for escape from broadly neutralizing antibodies. J Mol Biol 425: 1899–1914.

44. ChungRT, GordonFD, CurryMP, SchianoTD, EmreS, et al. (2013) Human monoclonal antibody MBL-HCV1 delays HCV viral rebound following liver transplantation: a randomized controlled study. Am J Transplant 13: 1047–1054.

45. DhillonS, WitteveldtJ, GathererD, OwsiankaAM, ZeiselMB, et al. (2010) Mutations within a conserved region of the hepatitis C virus E2 glycoprotein that influence virus-receptor interactions and sensitivity to neutralizing antibodies. J Virol 84: 5494–5507.

46. MorinTJ, BroeringTJ, LeavBA, BlairBM, RowleyKJ, et al. (2012) Human Monoclonal Antibody HCV1 Effectively Prevents and Treats HCV Infection in Chimpanzees. PLoS Pathog 8: e1002895.

47. HadlockKG, LanfordRE, PerkinsS, RoweJ, YangQ, et al. (2000) Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes. J Virol 74: 10407–10416.

48. TamuraK, StecherG, PetersonD, FilipskiA, KumarS (2013) MEGA6: Molecular Evolutionary Genetics Analysis version 6.0. Mol Biol Evol 30: 2725–2729.

49. KuikenC, YusimK, BoykinL, RichardsonR (2005) The Los Alamos hepatitis C sequence database. Bioinformatics 21: 379–384.

50. BankwitzD, SteinmannE, BitzegeioJ, CiesekS, FrieslandM, et al. (2010) Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes. J Virol 84: 5751–5763.

51. KeckZY, LiTK, XiaJ, Gal-TanamyM, OlsonO, et al. (2008) Definition of a conserved immunodominant domain on hepatitis C virus E2 glycoprotein by neutralizing human monoclonal antibodies. J Virol 82: 6061–6066.

52. KreyT, MeolaA, KeckZY, Damier-PiolleL, FoungSK, et al. (2013) Structural basis of HCV neutralization by human monoclonal antibodies resistant to viral neutralization escape. PLoS Pathog 9: e1003364.

53. MarshallRD (1974) The nature and metabolism of the carbohydrate-peptide linkages of glycoproteins. Biochem Soc Symp 17–26.

54. Schulz BL (2012) Beyond the Sequon: Sites of N-Glycosylation. In: Petrescu S, editor. Glycosylation. Rijeka, Croatia: InTech. pp. 21–40.

55. SchwarzF, LizakC, FanYY, FleurkensS, KowarikM, et al. (2011) Relaxed acceptor site specificity of bacterial oligosaccharyltransferase in vivo. Glycobiology 21: 45–54.

56. KowarikM, NumaoS, FeldmanMF, SchulzBL, CallewaertN, et al. (2006) N-linked glycosylation of folded proteins by the bacterial oligosaccharyltransferase. Science 314: 1148–1150.

57. KowarikM, YoungNM, NumaoS, SchulzBL, HugI, et al. (2006) Definition of the bacterial N-glycosylation site consensus sequence. EMBO J 25: 1957–1966.

58. KasturiL, ChenH, Shakin-EshlemanSH (1997) Regulation of N-linked core glycosylation: use of a site-directed mutagenesis approach to identify Asn-Xaa-Ser/Thr sequons that are poor oligosaccharide acceptors. Biochem J 323 (Pt 2): 415–419.

59. KasturiL, EshlemanJR, WunnerWH, Shakin-EshlemanSH (1995) The hydroxy amino acid in an Asn-X-Ser/Thr sequon can influence N-linked core glycosylation efficiency and the level of expression of a cell surface glycoprotein. J Biol Chem 270: 14756–14761.

60. NakabayashiH, TaketaK, MiyanoK, YamaneT, SatoJ (1982) Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res 42: 3858–3863.

61. IroM, WitteveldtJ, AngusAG, WoerzI, KaulA, et al. (2009) A reporter cell line for rapid and sensitive evaluation of hepatitis C virus infectivity and replication. Antiviral Res 83: 148–155.

62. WakitaT, PietschmannT, KatoT, DateT, MiyamotoM, et al. (2005) Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11: 791–796.